1244 GMT - Roche Holding is showing signs of improving its research-and-development productivity, Berenberg analysts say in a research note. The returns on the Swiss drugmaker's research-and-development investments this year are on track to reach 10%, above the 9% bar that is the average of both the sector as a whole and the company's own historic track record, Berenberg says, citing its own analysis. "Roche's valuation reflects this improved pipeline outlook," the analysts say. Shares fall 0.5%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments